Capacity of HIV1 p24 antigen screening to reduce the current residual risk of contracting HIV infection following transfusion
Fleurette F, Durieux, P
Record ID 31995000089
French
Authors' objectives:
Given that a screening procedure to detect Human Immunodeficiency Virus (HIV) itself rather than the immune response, was made available at the beginning of 1991, ANDEM was asked to assess the value of this screening test, in addition to HIV antibody screening, in blood transfusion.
Authors' results and conclusions:
We found that few cases of HIV infection following transfusion could be prevented each year by implementing HIV1 p24 antigen screening in all French blood banks. However, the experts thought that to announce the availability of such a new test would attract people recently involved in behaviour associated with a high risk of contracting HIV, which could lead to a paradoxical increased probability of HIV contamination following transfusion.
Authors' recommendations:
This new screening test can therefore not be recommended. Other output or dissemination activity: The HIV1 p24 antigen test has not been implemented.
Authors' methods:
Review
Details
Project Status:
Completed
URL for project:
http://www.has-sante.fr/
Year Published:
1991
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
France
MeSH Terms
- AIDS Serodiagnosis
- Blood Transfusion
- HIV
- HIV Antigens
Contact
Organisation Name:
L'Agence Nationale d'Accreditation d'Evaluation en Santé
Contact Address:
2 avenue du Stade de France, 93218 Saint-Denis La Plaine Cedex, France. Tel: +33 01 55 93 71 88; Fax: +33 01 55 93 74 35;
Contact Name:
sh.leerobin@has-sante.fr
Contact Email:
sh.leerobin@has-sante.fr
Copyright:
Agence Nationale pour le Developpement de l'Evaluation Medicale.
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.